Comparison · NCT02539225-e0a70dd8
Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin: Number of Participants With Anti-Ramucirumab Antibodies
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin: Number of Participants With Anti-Ramucirumab Antibodies. Trial comparisons, record NCT02539225-e0a70dd8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02539225-e0a70dd8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0109 | 0.00192 | 0.059 | wilson | |
| Risk in group 2 | 0.0333 | 0.0114 | 0.0935 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0225 | -0.0833 | 0.0305 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.326 | 0.0346 | 3.08 | log | |
| Odds ratio, group 1 over group 2 | 0.319 | 0.0325 | 3.12 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ramucirumab + S-1 + Oxaliplatin than on Placebo + S-1 + Oxaliplatin | 44.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ramucirumab + S-1 + Oxaliplatin | Part A: Participants received 8 milligram per kilogram (mg/kg) Ramucirumab by intravenous (IV) infusion on day 1 and day 8 of 21 days cycle in combination with oral dose of 80-120 mg/day S-1 on days 1 to14 and 100 milligram per square meter (mg/m\^2) Oxaliplatin administered by IV infusion on day 1 until disease progression or any other discontinuation criteria is met.~Part B:Participants received 8 mg/kg Ramucirumab by intravenous infusion on day 1 and day 15 of 28 days cycle in combination with 80 mg/m\^2 Paclitaxel on day 1, 8 and 15 by intravenous infusion until disease progression or any other discontinuation criteria is met. | 1 | 92 | OG000 |
| Group 2 | Placebo + S-1 + Oxaliplatin | Part A: Participants received placebo by intravenous (IV) infusion on day 1 and day 8 of 21 days cycle in combination with oral dose of 80-120 mg/day S-1 on days 1 to14 and 100 milligram per square meter (mg/m\^2) Oxaliplatin administered by IV infusion on day 1 until disease progression or any other discontinuation criteria is met.~Part B:Participants received Ramucirumab by intravenous infusion on day 1 and day 15 of 28 days cycle in combination with 80 mg/m\^2 Paclitaxel on day 1, 8 and 15 by intravenous infusion until disease progression or any other discontinuation criteria is met. | 3 | 90 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Anti-Ramucirumab Antibodies
- Description
Participant is considered as treatment emergent anti-drug antibody (TE ADA) positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post baseline result of ADA Present with titer \>= 20.
- Time frame
- Baseline through 25 months
- Population
- All randomized participants who received any quantity of study drug in part A and had at least one baseline \& post baseline antibody (ADA) measurement.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT number
- NCT02539225
- Phases
- PHASE2
- Conditions
- Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Ramucirumab, Placebo, S-1, Oxaliplatin, Paclitaxel
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2019-02-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02539225?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02539225-e0a70dd8